— Know what they know.
Not Investment Advice

ALIM NASDAQ

Alimera Sciences, Inc.
1W: +0.2% 1M: -0.9% 3M: +81.6% 1Y: +73.7% 3Y: +0.9%
$5.54
Last traded 2024-09-18 — delisted
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · $301.3M mcap · 13M float · 6.88% daily turnover

Balance Sheet Trends

Total Assets
$154M +260.4% ▲
5Y CAGR: +23.2%
Total Liabilities
$107M +69.2% ▲
5Y CAGR: +15.9%
Shareholders Equity
$46M +321.5% ▲
5Y CAGR: +76.2%
Cash & Investments
$12M +129.2% ▲
5Y CAGR: -1.5%
Total Debt
$67M +52.0% ▲
5Y CAGR: +11.9%
Net Debt
$55M +41.6% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2019FY2020FY2021FY2022FY2023
— Assets —
Cash$9M$11M$17M$5M$12M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$9M$11M$17M$5M$12M
Net Receivables$19M$17M$19M$20M$35M
Inventory$1M$3M$3M$2M$2M
Other Current Assets$33K$34K$34K$3M$4M
Total Current Assets$33M$35M$42M$29M$52M
Property, Plant & Equip.$2M$2M$4M$4M$4M
Goodwill & Intangibles$15M$13M$11M$9M$97M
Long-Term Investments$17M$15M$833K$183K$0
Other Non-Current Assets-$17M-$15M$0$0$52K
Total Non-Current Assets$18M$16M$16M$13M$101M
Total Assets$50M$51M$59M$43M$154M
— Liabilities —
Accounts Payable$7M$7M$9M$10M$8M
Short-Term Debt$0$1M$0$25M$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$2M$1M$2M$2M$3M
Total Current Liabilities$12M$12M$13M$40M$22M
Long-Term Debt$39M$42M$43M$19M$64M
Other Non-Current Liab.$4M$4M$5M$5M$21M
Total Non-Current Liabilities$43M$46M$49M$24M$85M
Total Liabilities$55M$59M$61M$63M$107M
— Equity —
Common Stock$50K$57K$69K$70K$524K
Retained Earnings-$388M-$393M-$397M-$415M-$418M
Accumulated OCI-$1M-$553K-$2M-$3M$2M
Total Stockholders Equity-$4M-$8M-$3M-$21M$46M
Total Liabilities & Equity$50M$51M$59M$43M$154M
— Key Metrics —
Total Debt$39M$45M$44M$44M$67M
Net Debt$30M$34M$27M$39M$55M
Total Investments$17M$15M$833K$183K$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms